Article(id=1327673209094254753, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327673173845324667, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2022.04.005, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1631808000000, receivedDateStr=2021-09-17, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794471560022, onlineDateStr=2026-11-12, pubDate=1649520000000, pubDateStr=2022-04-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794471560022, onlineIssueDateStr=2026-11-12, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794471560022, creator=13701087609, updateTime=1794471560022, updator=13701087609, issue=Issue{id=1327673173845324667, tenantId=1146029695717560320, journalId=1319690259887390882, year='2022', volume='53', issue='4', pageStart='425', pageEnd='590', issueExtLink='null', onlineDate='null', pubDate='1649520000000', pubDateStr='2022-04-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794471551619, creator='13701087609', updateTime=1794472266725, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1327676173842231314, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327673173845324667, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1327676173842231315, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327673173845324667, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=464, endPage=473, ext={EN=ArticleExt(id=1327673209333330082, articleId=1327673209094254753, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Small Molecule Cyclin-dependent Kinase 4/6 Inhibitor Drugs and Their Patent Research, columnId=1327671134809600231, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Review, runingTitle=null, highlight=null, articleAbstract=
In this study, five small-molecule cyclin-dependent kinase 4/6(CDK4/6) inhibitors, marketed at home and abroad, are analyzed and researched in detail, so does their patent information. To provide practical patent information and references for Chinese pharmaceutical companies to establish and develop projects of CDK4/6 inhibitors for innovative or generic drugs, as well as new patent mining, patent protection and layout, this study mainly focuses on the patents of product, crystalline form, salt form, process, formulation, drug combination, new use and development derivatives.
, authors=Fan GE
1, Jian SUN
2, Lu HUANG
3, 4, *, authorsList=Fan GE, Jian SUN, Lu HUANG, authorCompany=null, correspAuthors=Lu HUANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1327673210063138979, articleId=1327673209094254753, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=小分子周期蛋白依赖性激酶4/6抑制剂药物及其专利研究, columnId=1327671135019315436, journalTitle=中国医药工业杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=
本研究重点对国内外已上市的5个小分子周期蛋白依赖性激酶4/6(CDK4/6)抑制剂药物及其专利信息进行解读,详细分析和研究了各药物在不同技术主题如化合物、晶型、盐型、制备工艺、药物制剂、药物组合物和(或)联合给药、药物新用途、衍生物等方面的专利情况,以期为我国医药企业进行CDK4/6抑制剂的创新药或仿制药产品立项与开发,以及进行新的专利挖掘、专利保护与布局时,提供有效的专利信息和文献依据。
, authors=葛凡
1, 孙建
2, 黄璐
3, 4, *, authorsList=葛凡, 孙建, 黄璐, authorCompany=null, correspAuthors=黄璐, authorNote=
葛凡(1980—),男,博士,专利代理师,诉讼代理人,从事医药知识产权工作。
, correspAuthorsNote=
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=AsVJrVsF+qlM7Dj3u7XTOA==, magXml=EuUX967XzAVGx/pHc45rNg==, pdfUrl=null, pdf=+VfBFpy9i+GkNboO/lAc7w==, pdfFileSize=1662716, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=CsjVKSfN3alN0UBYLrOmYQ==, mapNumber=null, fund=null)}, authors=[Author(id=1327673211837329586, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327673211946381492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673211837329586, language=EN, stringName=Fan GE, firstName=Fan, middleName=null, lastName=GE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.FIWIS Intellectual Property Law Firm, Beijing 100032, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673212009296053, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673211837329586, language=CN, stringName=葛凡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, address=
1.北京孚睿湾知识产权代理事务所,北京 100032, bio={"content":"
葛凡(1980—),男,博士,专利代理师,诉讼代理人,从事医药知识产权工作。
"}, bioImg=null, bioContent=
葛凡(1980—),男,博士,专利代理师,诉讼代理人,从事医药知识产权工作。
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673211464036516, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=1., ext=[AuthorCompanyExt(id=1327673211472425125, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.FIWIS Intellectual Property Law Firm, Beijing 100032), AuthorCompanyExt(id=1327673211480813734, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.北京孚睿湾知识产权代理事务所,北京 100032)])]), Author(id=1327673212076404919, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327673212156096697, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212076404919, language=EN, stringName=Jian SUN, firstName=Jian, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
2, address=
2.Kanazawa Institute of Technology, Tokyo, Japan 105-0002, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673212290314426, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212076404919, language=CN, stringName=孙建, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
2, address=
2.金泽工业大学,日本 东京都 105-0002, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673211556311207, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=2., ext=[AuthorCompanyExt(id=1327673211564699816, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Kanazawa Institute of Technology, Tokyo, Japan 105-0002), AuthorCompanyExt(id=1327673211568894121, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.金泽工业大学,日本 东京都 105-0002)])]), Author(id=1327673212403560636, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=47153437@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1327673212525195455, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212403560636, language=EN, stringName=Lu HUANG, firstName=Lu, middleName=null, lastName=HUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
3, 4, *, address=
3.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205
4.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327673212617470144, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, authorId=1327673212403560636, language=CN, stringName=黄璐, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
3, 4, *, address=
3.武汉工程大学化工与制药学院,湖北 武汉 430205
4.武汉大学药学院,湖北 武汉 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327673211627614378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=3., ext=[AuthorCompanyExt(id=1327673211656974507, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205), AuthorCompanyExt(id=1327673211673751724, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.武汉工程大学化工与制药学院,湖北 武汉 430205)]), AuthorCompany(id=1327673211753443502, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=4., ext=[AuthorCompanyExt(id=1327673211766026415, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
4.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071), AuthorCompanyExt(id=1327673211774415024, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
4.武汉大学药学院,湖北 武汉 430071)])])], keywords=[Keyword(id=1327673212726522050, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=1, keyword=CDK4/6 inhibitor), Keyword(id=1327673212785242307, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=2, keyword=palbociclib), Keyword(id=1327673212873322692, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=3, keyword=ribociclib), Keyword(id=1327673212936237253, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=4, keyword=abemaciclib), Keyword(id=1327673212990763206, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=5, keyword=trilaciclib), Keyword(id=1327673213049483463, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=6, keyword=dalpiciclib), Keyword(id=1327673213116592328, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=EN, orderNo=7, keyword=patent research), Keyword(id=1327673213175312585, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=1, keyword=CDK4/6抑制剂), Keyword(id=1327673213234032842, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=2, keyword=哌柏西利), Keyword(id=1327673213284364491, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=3, keyword=利柏西利), Keyword(id=1327673213359861964, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=4, keyword=阿贝西利), Keyword(id=1327673213418582221, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=5, keyword=曲拉西利), Keyword(id=1327673213489885390, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=6, keyword=达尔西利), Keyword(id=1327673213565382863, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, language=CN, orderNo=7, keyword=专利研究)], refs=[Reference(id=1327673213741543633, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=TOOGOOD P L, HARVEY P J, REPINE J T,
et al.Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 [J].
J Med Chem, 2005,
48(7): 2388-2406., articleTitle=null, refAbstract=null), Reference(id=1327673213825429715, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=VANDERWEL S N, HARVEY P J, MCNAMARA D J,
et al.Pyrido[2,3-
d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4 [J].
J Med Chem, 2005,
48(7):2371-2387., articleTitle=null, refAbstract=null), Reference(id=1327673213905121492, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=PARDEE A B.G1 events and regulation of cell proliferation[J].
Science, 1989,
246(4930): 603-608., articleTitle=null, refAbstract=null), Reference(id=1327673213963841749, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=FINN R S, DERING J, CONKLIN D,
et al.PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines
in vitro [J].
Breast Cancer Res,2009,
11(5): R77., articleTitle=null, refAbstract=null), Reference(id=1327673214022562006, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=VANARSDALE T, BOSHOFF C, ARNDT K T,
et al.Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment [J].
Clin Cancer Res, 2015,
21(13): 2905-2910., articleTitle=null, refAbstract=null), Reference(id=1327673215771586775, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=ASGHAR U, WITKIEWICZ A K, TURNER N C,
et al.The history and future of targeting cyclin-dependent kinases in cancer therapy [J].
Nat Rev Drug Discov, 2015,
14(2):130-146., articleTitle=null, refAbstract=null), Reference(id=1327673215863861464, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=KLEIN M E, KOVATCHEVA M, DAVIS L E,
et al.CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought [J].
Cancer Cell, 2018,
34(1):9-20., articleTitle=null, refAbstract=null), Reference(id=1327673215922581721, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Clarivate Analytics公司.Cortellis数据库[EB/OL].[2021-11-23].
https://www.cortellis.com/intelligence., articleTitle=null, refAbstract=null), Reference(id=1327673215989690586, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=DHILLON S.Palbociclib: first global approval [J].
Drugs,2015,
75(5): 543-551., articleTitle=null, refAbstract=null), Reference(id=1327673216056799451, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=LU J.Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer [J].
J Hematol Oncol, 2015,
8(1): 98., articleTitle=null, refAbstract=null), Reference(id=1327673216136491228, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Drugs@FDA: FDA-approved drugs-Ibrance(palbociclib) NDA #207103 [EB/OL].[2021-08-12].
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103., articleTitle=null, refAbstract=null), Reference(id=1327673216203600093, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Palbociclib(Ibrance)[EB/OL].[2021-08-12].
https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance., articleTitle=null, refAbstract=null), Reference(id=1327673216287486174, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Drugs@FDA: FDA-approved drugs-Ibrance(palbociclib) NDA #212436 [EB/OL].[2021-08-12].
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212436., articleTitle=null, refAbstract=null), Reference(id=1327673216346206431, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Ribociclib (Kisqali)[EB/OL].[2021-08-12].
https://www.fda.gov/drugs/resources-information-approved-drugs/ribociclib-kisqali., articleTitle=null, refAbstract=null), Reference(id=1327673216417509600, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=BRAAL C L, JONGBLOED E M, WILTING S M,
et al.Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences [J].
Drugs, 2021,
81(3): 317-331., articleTitle=null, refAbstract=null), Reference(id=1327673216484618465, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=KNUDSEN E S, WITKIEWICZ A K.Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER
+/HER2
- breast cancer [J].
Oncotarget,2016,
7(43): 69111-69123., articleTitle=null, refAbstract=null), Reference(id=1327673216551727330, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.FDA approves abemaciclib for HR-positive, HER2-negative breast cancer [EB/OL].[2021-08-12].
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-hr-positive-her2-negative-breast-cancer., articleTitle=null, refAbstract=null), Reference(id=1327673216623030499, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=SLEDGE G W Jr, TOI M, NEVEN P,
et al.MONARCH 2: abemaciclib in combination with fulvestrant in women with HR
+/HER2 advanced breast cancer who had progressed while receiving endocrine therapy [J].
J Clin Oncol, 2017,
35(25): 2875-2884., articleTitle=null, refAbstract=null), Reference(id=1327673216732082404, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=GOETZ M P, TOI M, CAMPONE M,
et al.MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J].
J Clin Oncol, 2017,
35(32): 3638-3646., articleTitle=null, refAbstract=null), Reference(id=1327673216807579877, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer[EB/OL].[2021-08-12].
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-initial-therapy-hr-positive-her2-negative-metastatic-breast-cancer., articleTitle=null, refAbstract=null), Reference(id=1327673216870494438, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=李瑞鹏,夏广新,赵建宏,等.阿贝西利的合成研究进展[J].中国医药工业杂志,2021,
52(9):1142-1153., articleTitle=null, refAbstract=null), Reference(id=1327673216945991911, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=PARYLO S, VENNEPUREDDY A, DHAR V,
et al.Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment [J].
J Oncol Pharm Pract,2019,
25(1): 110-129., articleTitle=null, refAbstract=null), Reference(id=1327673217021489384, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.FDA approves drug to reduce bone marrow suppression caused by chemotherapy [EB/OL].[2021-08-12].
https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy., articleTitle=null, refAbstract=null), Reference(id=1327673217122152681, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=先声药业官网.先声药业和G1 Therapeutics宣布签署有关Trilaciclib产品在大中华地区的独家许可协议[EB/OL].[2021-08-12].
https://www.simcere.com/news/detail.aspx?mtt=98., articleTitle=null, refAbstract=null), Reference(id=1327673217193455850, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=U.S.FDA.Drugs@FDA: FDA-Approved Drugs, labels for NDA 214200 [EB/OL].[2021-08-12].
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1327673217268953323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=XU B, ZHANG Q, ZHANG P,
et al.Dalpiciclib versus placebo plus fulvestrant in HR
+/HER2
- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): amulticenter, randomized, phase 3 study [J].
J Clin Oncol, 2021,
39(15_suppl): 1002., articleTitle=null, refAbstract=null), Reference(id=1327673217357033708, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=黄璐,王亚楠,陈进,等.新丝裂原激活蛋白激酶激酶1/2抑制剂:司美替尼[J].中国新药与临床杂志,2021,
40(8):562-568., articleTitle=null, refAbstract=null), Reference(id=1327673217453502701, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=黄璐,古双喜,洪怡.选择性转染重排酪氨酸激酶抑制剂概述及其专利研究[J].中国医药工业杂志,2021,
52(10):1291-1296., articleTitle=null, refAbstract=null), Reference(id=1327673217516417262, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=黄璐,余浩,张长春,等.药品研发过程中的知识产权制度及运用[J].中国新药杂志,2019,
28(1):10-16., articleTitle=null, refAbstract=null)], funds=[Fund(id=1327673213640880336, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, awardId=18BFX168, language=CN, fundingSource=国家社会科学基金项目(18BFX168), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1327673211464036516, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=1., ext=[AuthorCompanyExt(id=1327673211472425125, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.FIWIS Intellectual Property Law Firm, Beijing 100032), AuthorCompanyExt(id=1327673211480813734, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211464036516, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.北京孚睿湾知识产权代理事务所,北京 100032)]), AuthorCompany(id=1327673211556311207, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=2., ext=[AuthorCompanyExt(id=1327673211564699816, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Kanazawa Institute of Technology, Tokyo, Japan 105-0002), AuthorCompanyExt(id=1327673211568894121, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211556311207, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.金泽工业大学,日本 东京都 105-0002)]), AuthorCompany(id=1327673211627614378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=3., ext=[AuthorCompanyExt(id=1327673211656974507, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205), AuthorCompanyExt(id=1327673211673751724, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211627614378, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
3.武汉工程大学化工与制药学院,湖北 武汉 430205)]), AuthorCompany(id=1327673211753443502, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, xref=4., ext=[AuthorCompanyExt(id=1327673211766026415, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
4.School of Pharmacutical Sciences, Wuhan University, Wuhan 430071), AuthorCompanyExt(id=1327673211774415024, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327673209094254753, companyId=1327673211753443502, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
4.武汉大学药学院,湖北 武汉 430071)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2022.04.005, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2022.04.005, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2022.04.005, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2022.04.005, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1649520000000, fullTextJson=null, articleText=null, reference=null)